The journey from drug development to patient access remains one of healthcare’s most enduring challenges. As therapies become more advanced, the complexity of ensuring that treatments reach the appropriate patients at the right time has increased significantly.

Data experts in Specialty and Rare Diseases at Claritas Rx have been tackling this issue since 2011, when they began enhancing how biopharmaceutical manufacturers assess their specialty product performance. The company has transformed from a small-channel data consultancy into a leader in patient-level data integration and analytics, serving a diverse client base that includes emerging biotechnology firms launching their first specialty products and global manufacturers with established portfolios.

This data-driven strategy has revolutionized the understanding of patient journeys, particularly through the company’s collaboration with the global pharmaceutical firm Servier. What started in 2020 as a targeted partnership on two oncology drugs has expanded to encompass Servier’s entire cancer treatment portfolio.

Athena Uzzo, Senior Vice President of Customer Experience at Claritas Rx, characterizes the relationship as “a collaborative partnership” focused on addressing Servier’s specific business inquiries.

“We manage the data aggregation and collaborate with all of their partners across those brands, while also providing analytical insights,” she states.

Claritas Rx was established with a clear mission. “Our company was founded to ensure that patients with chronic and life-threatening diseases receive the support necessary to maximize the benefits of their therapy,” Athena clarifies.

To read the full article in the magazine, click HERE.